F

FDC Ltd

Q4 FY17Pharmaceuticals & Biotechnology

FDC Q4 FY17 earnings call: Revenue & Margins

Q4 FY17 investor presentation: what the company reported on revenue, margins and projects.

Price₹346
Market cap₹5.7K Cr
P/E18.6
Updated25 Sept 2026
Read3 min read

Based on FDC Ltd's Q4 FY17 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

For Q4 FY 2017, total revenue was Rs. The investor presentation does not explicitly provide EBITDA, operating margin, profit after tax (PAT), year-on-year changes, or any explicit margin outlook figures for the quarter.

From FDC Ltd's Q4 FY17 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • For Q4 FY 2017, total revenue was Rs. 256 Crs, up from Rs. 249 Crs in Q4 FY 2016.
  • The year-on-year revenue growth for Q4 FY 2017 was 3.7%.
  • Domestic sales reached Rs. 256 Crs in Q4 FY 2017 with a 3.7% growth, while the Indian Pharmaceutical Market (IPM) grew by 10.3% in the same period.
  • Full-year revenue for FY 2017 was Rs. 1,046 Crs, up from Rs. 1,010 Crs in FY 2016.

2 more points management made on revenue & sales performance

Profitability & Margins

See what FDC Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The investor presentation does not explicitly detail any capex, capacity expansion, or new plant/project with specific amounts, status, or timelines. - Pages 5 and 6 mention existing manufacturing setups at Roha, Waluj, Goa I, II, III, Sinnar, and BFS-Waluj but provide no information on new plants or expansions. - No capex figures or project timelines are stated anywhere in the document. - No specific future capacity expansion plans or ongoing projects are described. In summary, the presentation does not provide any details regarding capex or capacity expansion initiatives.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what FDC Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not report any details on order book, order inflow, or pending orders. - There is no mention or data related to order book status. - No figures or commentary on order inflow are provided. - Pending orders or backlogs are not discussed anywhere in the report. The contents mainly focus on financial results, sales performance, business highlights, and contact information.

FDC Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹585 Cr, net profit ₹103 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Unichem Laboratories Ltd (Q4 FY17)

    Quarter ended March 31, 2017 revenue from operations: INR 18,735 lakhs, up 7% YoY (from INR 17,447 lakhs in Q4 FY16) (Page 38). Key concall takeaways from…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were FDC Ltd Q4 FY17 results?

For Q4 FY 2017, total revenue was Rs. The investor presentation does not explicitly provide EBITDA, operating margin, profit after tax (PAT), year-on-year changes, or any explicit margin outlook figures for the quarter.

What is FDC Ltd share price analysis?

FDC Ltd currently shows a neutral. The stock trades at a P/E of 18.6 with a market cap of ₹5,739 Cr. Investors should review the full earnings analysis for detailed insights.

Is FDC Ltd planning capital expenditure?

The investor presentation does not explicitly detail any capex, capacity expansion, or new plant/project with specific amounts, status, or timelines.

Keep FDC Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.